CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Methylnaltrexone bromide

Last Updated: May 7, 2008
Result type: Reports
Project Number: SR0135-000
Product Line: Reimbursement Review

Generic Name: Methylnaltrexone bromide

Brand Name: Relistor

Manufacturer: Wyeth Canada

Therapeutic Area: Constipation, Opioid-induced

Indications: Constipation, Opioid-induced

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: January 28, 2009

Recommendation Type: Do not list